
Figma targets $16.4 billion valuation in IPO
The San Francisco-based company, along with some investors, is eyeing proceeds of up to $1.03 billion by selling nearly 37 million shares priced between $25 and $28 each, it said on Monday.
The listing could be a major milestone for Figma, coming more than a year after its $20 billion sale to Adobe failed due to regulatory hurdles in Europe and the UK.
An equities rally and a bunch of strong debuts recently have helped remove the IPO market overhang. Figma is expected to start trading close on the heels of stablecoin giant Circle, which debuted with eye-popping gains last month and has continued surging since.
As a major technology player that appears supportive of bitcoin, Figma has already drawn attention on social media.
The company had around $70 million invested in Bitwise's bitcoin exchange-traded fund as of March 31 and intends to allocate a further $30 million to bitcoin, its filing showed.
Figma expects to list under the symbol 'FIG'. Morgan Stanley, Goldman Sachs, Allen & Co and J.P. Morgan are among the underwriters for the offering.
It was valued at $12.5 billion in a tender offer last year that allowed employees and early investors to cash out a portion of their stake.
'Big swings'
Figma is a cloud-based design platform that allows users to collaboratively create and edit apps, websites and software interfaces.
Its customers include ServiceNow, Workday and SAP. Its revenue rose 46% in the first three months of 2025, while net income jumped three-fold.
'Figma's product is its primary marketing engine. Its collaborative nature fosters viral, bottoms-up adoption, leading to a best-in-class sales efficiency,' said Tomasz Tunguz, founder of venture capital firm Theory Ventures.
The company has also signaled it may take 'big swings' with M&A, with co-founder and CEO Dylan Field saying it is prepared to 'make decisions that may not seem immediately rational.'
Still, the listing will take place at a time when the industry landscape is shifting. While Figma is sharpening its focus on AI, it has also warned that design tools driven by the technology could make some customers less reliant on its platform.
The company has noted that restrictive immigration policies could impact its ability to recruit talent, citing past adjustments to hiring practices due to changes in visa assessment frameworks.
A majority of its revenue in 2024 came from outside the United States, exposing it to potential demand softness if international clients tighten their purse strings in response to tariffs.
Renewed trade tensions could also add to the caution among IPO investors, risking further disruption.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Thermo Fisher beats quarterly estimates on resilient demand for its tools and services
(Reuters) -Thermo Fisher on Wednesday beat Wall Street estimates for second-quarter profit and revenue, helped by steady demand for its products and services used for developing therapies. Shares of the medical equipment maker were up 2.5% in premarket trading. The company joins peers such as Danaher in beating quarterly profit estimates, citing strong demand from the industry for tools and services used to make vaccines and therapies. Danaher said on Tuesday it is seeing a robust number of clinical trials and therapies under development, with steady demand from its pharmaceutical clients. On an adjusted basis, Thermo Fisher reported a profit of $5.36 per share for the quarter ended June 28, beating analysts' estimate of $5.22 per share, as per data compiled by LSEG. The company said its business strategy called "practical process improvement" is helping adjust its supply chains in the tariff environment and to actively manage its cost base. Last week, the company said it will buy French drugmaker Sanofi's New Jersey manufacturing site, "to meet growing demand from pharma and biotech customers." The Waltham Massachusetts-based company's quarterly revenue rose 3% to $10.85 billion, compared to analyst estimates of $10.68 billion. Sales at its laboratory products segment, which makes up more than half of Thermo Fisher's total sales came in at $6 billion, above estimates of $5.79 billion. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Highly shorted Krispy Kreme, GoPro jump as meme stock rally continues
(Reuters) -Shares of some highly-shorted companies, including Krispy Kreme and GoPro, jumped in premarket trading on Wednesday, aided by their names trending on social media forums a day after retail traders piled into department store company Kohl's. Doughnut chain Krispy Kreme jumped 16.1%, building on a near 27% surge on Tuesday. About 14% of Krispy Kreme's outstanding shares available for trading are shorted, according to data compiled by LSEG. Camera maker GoPro also surged about 47% to $2.01. Short interest on the stock was last at 7.7%. Another highly shorted stock - with short interest at 36.7% - was plant-based meat company Beyond Meat, whose shares jumped 10.4% on Wednesday. The growing interest in heavily shorted stocks comes after Kohl's surged 37.6% higher in volatile trading on Tuesday on the back of high retail interest. Mom-and-pop traders bought $9.64 million of its shares that day, the most by this category of investors in about three years, according to data from Vanda Research. Kohl's was flat in premarket trading on Wednesday but is the third most trending ticker on Stocktwits, a retail investor-focused social media platform. Among other highly shorted names, online gifts retailer rose 8.1%. Opendoor Technologies, which has rocketed 440% so far this month, was down 2.6% on Wednesday.

Yahoo
22 minutes ago
- Yahoo
Thermo Fisher shares climb as Q2 top and bottom line exceed estimates
-- Thermo Fisher Scientific Inc (NYSE:TMO) reported second-quarter earnings that topped expectations, with revenue also coming in ahead of forecasts. The company reported adjusted EPS of $5.36, beating the analyst estimate of $5.23. Revenue rose 3% from a year earlier to $10.85 billion, above the $10.68 billion consensus. Shares in the medical equipment maker were up 2.3% in premarket trading Wednesday as of 06:06 ET. 'Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment," said Marc N. Casper, chairman, president, and CEO of Thermo Fisher Scientific. Adjusted operating income reached $2.38 billion, slightly up from $2.35 billion in the same period last year. Adjusted operating margin slipped to 21.9% from 22.3% a year ago. Related articles Thermo Fisher shares climb as Q2 top and bottom line exceed estimates These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia If Powell goes, does Fed trust go with him?